<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04500000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P03951</UniProt_ID>
  <Seq_Length>625</Seq_Length>
  <Molecule_Weight>70109</Molecule_Weight>
  <KEGG_ID>hsa:2160</KEGG_ID>
  <Orthology_ID>K01323</Orthology_ID>
  <EBI_ID>EBI-1041019</EBI_ID>
  <Function_Summary>Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.</Function_Summary>
  <Catalytic_Mechanism>Selective cleavage of Arg-|-Ala and Arg-|-Val bonds in factor IX to form factor IXa.</Catalytic_Mechanism>
  <Pfam_ID>PF00024:PAN_1@@PF00089:Trypsin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>5</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Coagulation factor XIa heavy chain</Alias>
      <Alias>Plasma thromboplastin antecedent</Alias>
      <Alias>FXI</Alias>
      <Alias>Coagulation factor XIa light chain</Alias>
      <Alias>PTA</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heparin, any member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha1-4-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues.</Detail>
      <Keyword>Heparin binding</Keyword>
      <Ontology_ID>GO:0008201</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).</Detail>
      <Keyword>Protein binding</Keyword>
      <Ontology_ID>GO:0005515</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>341</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>322</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>618</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>66</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>301</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>430</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>308</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>493</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>101</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>594</Position>
      <Original>Ser</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>404</Position>
      <Original>Thr</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>399</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>266</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>511</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>246</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>460</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>244</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>255</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>56</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>263</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>565</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>418</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>339</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>587</Position>
      <Original>Trp</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>326</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>151</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>34</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>320</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>538</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>270</Position>
      <Original>Lys</Original>
      <Variation>Ile</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which inactive plasminogen is processed to active plasmin. This process includes cleavage at an internal Arg-Val site to form an N-terminal A-chain and C-terminal B-chain held together by a disulfide bond, and can include further proteolytic cleavage events to remove the preactivation peptide.</Detail>
      <Keyword>Plasminogen activation</Keyword>
      <Ontology_ID>GO:0031639</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates, maintains or increases the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots.</Detail>
      <Keyword>Positive regulation of fibrinolysis</Keyword>
      <Ontology_ID>GO:0051919</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, intrinsic pathway</Keyword>
      <Ontology_ID>GO:0007597</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>17</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>22</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MIFLYQVVHFILFTSVSGECVTQLLKDTCFEGGDITTVFTPSAKYCQVVCTYHPRCLLFTFTAESPSEDPTRWFTCVLKDSVTETLPRVNRTAAISGYSFKQCSHQISACNKDIYVDLDMKGINYNSSVAKSAQECQERCTDDVHCHFFTYATRQFPSLEHRNICLLKHTQTGTPTRITKLDKVVSGFSLKSCALSNLACIRDIFPNTVFADSNIDSVMAPDAFVCGRICTHHPGCLFFTFFSQEWPKESQRNLCLLKTSESGLPSTRIKKSKALSGFSLQSCRHSIPVFCHSSFYHDTDFLGEELDIVAAKSHEACQKLCTNAVRCQFFTYTPAQASCNEGKGKCYLKLSSNGSPTKILHGRGGISGYTLRLCKMDNECTTKIKPRIVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV</Protein_Seq>
    <DNA_Seq>AGGCACACAGGCAAAATCAAGTTCTACATCTGTCCCTGTGTATGTCACTTGTTTGAATACGAAATAAAATTAAAAAAATAAATTCAGTGTATTGAGAAAGCAAGCAATTCTCTCAAGGTATATTTCTGACATACTAAGATTTTAACGACTTTCACAAATATGCTGTACTGAGAGAGAATGTTACATAACATTGAGAACTAGTACAAGTAAATATTAAAGTGAAGTGACCATTTCCTACACAAGCTCATTCAGAGGAGGATGAAGACCATTTTGGAGGAAGAAAAGCACCCTTATTAAGAATTGCAGCAAGTAAGCCAACAAGGTCTTTTCAGGATGATTTTCTTATATCAAGTGGTACATTTCATTTTATTTACTTCAGTTTCTGGTGAATGTGTGACTCAGTTGTTGAAGGACACCTGCTTTGAAGGAGGGGACATTACTACGGTCTTCACACCAAGCGCCAAGTACTGCCAGGTAGTCTGCACTTACCACCCAAGATGTTTACTCTTCACTTTCACGGCGGAATCACCATCTGAGGATCCCACCCGATGGTTTACTTGTGTCCTGAAAGACAGTGTTACAGAAACACTGCCAAGAGTGAATAGGACAGCAGCGATTTCTGGGTATTCTTTCAAGCAATGCTCACACCAAATAAGCGCTTGCAACAAAGACATTTATGTGGACCTAGACATGAAGGGCATAAACTATAACAGCTCAGTTGCCAAGAGTGCTCAAGAATGCCAAGAAAGATGCACGGATGACGTCCACTGCCACTTTTTCACGTACGCCACAAGGCAGTTTCCCAGCCTGGAGCATCGTAACATTTGTCTACTGAAGCACACCCAAACAGGGACACCAACCAGAATAACGAAGCTCGATAAAGTGGTGTCTGGATTTTCACTGAAATCCTGTGCACTTTCTAATCTGGCTTGTATTAGGGACATTTTCCCTAATACGGTGTTTGCAGACAGCAACATCGACAGTGTCATGGCTCCCGATGCTTTTGTCTGTGGCCGAATCTGCACTCATCATCCCGGTTGCTTGTTTTTTACCTTCTTTTCCCAGGAATGGCCCAAAGAATCTCAAAGAAATCTTTGTCTCCTTAAAACATCTGAGAGTGGATTGCCCAGTACACGCATTAAAAAGAGCAAAGCTCTTTCTGGTTTCAGTCTACAAAGCTGCAGGCACAGCATCCCAGTGTTCTGCCATTCTTCATTTTACCATGACACTGATTTCTTGGGAGAAGAACTGGATATTGTTGCTGCAAAAAGTCACGAGGCCTGCCAGAAACTGTGCACCAATGCCGTCCGCTGCCAGTTTTTTACCTATACCCCAGCCCAAGCATCCTGCAACGAAGGGAAGGGCAAGTGTTACTTAAAGCTTTCTTCAAACGGATCTCCAACTAAAATACTTCACGGGAGAGGAGGCATCTCTGGATACACATTAAGGTTGTGTAAAATGGATAATGAGTGTACCACCAAAATCAAGCCCAGGATCGTTGGAGGAACTGCGTCTGTTCGTGGTGAGTGGCCGTGGCAGGTGACCCTGCACACAACCTCACCCACTCAGAGACACCTGTGTGGAGGCTCCATCATTGGAAACCAGTGGATATTAACAGCCGCTCACTGTTTCTATGGGGTAGAGTCACCTAAGATTTTGCGTGTCTACAGTGGCATTTTAAATCAATCTGAAATAAAAGAGGACACATCTTTCTTTGGGGTTCAAGAAATAATAATCCATGATCAGTATAAAATGGCAGAAAGCGGGTATGATATTGCCTTGTTGAAACTGGAAACCACAGTGAATTACACAGATTCTCAACGACCCATATGCCTGCCTTCCAAAGGAGATAGAAATGTAATATACACTGATTGCTGGGTGACTGGATGGGGGTACAGAAAACTAAGAGACAAAATACAAAATACTCTCCAGAAAGCCAAGATACCCTTAGTGACCAACGAAGAGTGCCAGAAGAGATACAGAGGACATAAAATAACCCATAAGATGATCTGTGCCGGCTACAGGGAAGGAGGGAAGGACGCTTGCAAGGGAGATTCGGGAGGCCCTCTGTCCTGCAAACACAATGAGGTCTGGCATCTGGTAGGCATCACGAGCTGGGGCGAAGGCTGTGCTCAAAGGGAGCGGCCAGGTGTTTACACCAACGTGGTCGAGTACGTGGACTGGATTCTGGAGAAAACTCAAGCAGTGTGAATGGGTTCCCAGGGGCCATTGGAGTCCCTGAAGGACCCAGGATTTGCTGGGAGAGGGTGTTGAGTTCACTGTGCCAGCATGCTTCCTCCACAGTAACACGCTGAAGGGGCTTGGTGTTTGTAAGAAAATGCTAGAAGAAAACAAACTGTCACAAGTTGTTATGTCCAAAACTCCCGTTCTATGATCGTTGTAGTTTGTTTGAGCATTCAGTCTCTTTGTTTTTGATCACGCTTCTATGGAGTCCAAGAATTACCATAAGGCAATATTTCTGAAGATTACTATATAGGCAGATATAGCAGAAAATAACCAAGTAGTGGCAGTGGGGATCAGGCAGAAGAACTGGTAAAAGAAGCCACCATAAATAGATTTGTTCGATGAAAGATGAAAACTGGAAGAAAGGAGAACAAAGACAGTCTTCACCATTTTGCAGGAATCTACACTCTGCCTATGTGAACACATTTCTTTTGTAAAGAAAGAAATTGATTGCATTTAATGGCAGATTTTCAGAATAGTCAGGAATTCTTGTCATTTCCATTTTAAAATATATATTAAAAAAAATCAGTTCGAGTAGACACGAGCTAAGAGTGAATGTGAAGATAACAGAATTTCTGTGTGGAAGAGGATTACAAGCAGCAATTTACCTGGAAGTGATACCTTAGGGGCAATCTTGAAGATACACTTTCCTGAAAAATGATTTGTGATGGATTGTATATTTATTTAAAATATCTTGGGAGGGGAGGCTGATGGAGATAGGGAGCATGCTCAAACCTCCCTAAGACAAGCTGCTGCTGTGACTATGGGCTCCCAAAGAGCTAGATCGTATATTTATTTGACAAAAATCACCATAGACTGCATCCATACTACAGAGAAAAAACAATTAGGGCGCAAATGGATAGTTACAGTAAAGTCTTCAGCAAGCAGCTGCCTGTATTCTAAGCACTGGGATTTTCTGTTTCGTGCAAATATTTATCTCATTATTGTTGTGATCTAGTTCAATAACCTAGAATTTGAATTGTCACCACATAGCTTTCAATCTGTGCCAACAACTATACAATTCATCAAGTGTG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Megakaryocytes</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Platelets</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>F11</Gene_Name>
    <Gene_ID>2160</Gene_ID>
    <Genbank_ACCN>NM_000128</Genbank_ACCN>
    <Protein_ACCN>NP_000119</Protein_ACCN>
    <HGNC_ID>3529</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2160</Gene_URL>
    <UCSC_ID>uc003iza.1</UCSC_ID>
    <EMBL_ID>ENSG00000088926</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P23827</Uniprot_ID>
      <Gene_Name>eco</Gene_Name>
      <EBI_ID>EBI-1029159</EBI_ID>
      <PPI_EBI_URL>EBI-1041019,EBI-1029159</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Hemophilia B</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia_b?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Von Willebrand's Disease</Disease_Name>
      <Disease_Detail>Von Willebrand's Disease</Disease_Detail>
      <Disease_DB>VNW001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/von_willebrands_disease?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Viii Deficiency</Disease_Name>
      <Disease_Detail>Factor Viii Deficiency</Disease_Detail>
      <Disease_DB>FCT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_viii_deficiency?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Hemophilia</Disease_Name>
      <Disease_Detail>Acquired Hemophilia</Disease_Detail>
      <Disease_DB>ACQ014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_hemophilia?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Afibrinogenemia</Disease_Name>
      <Disease_Detail>Afibrinogenemia</Disease_Detail>
      <Disease_DB>AFB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/afibrinogenemia?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thromboembolism</Disease_Name>
      <Disease_Detail>Thromboembolism</Disease_Detail>
      <Disease_DB>THR079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thromboembolism?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency, Autosomal Recessive</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency_autosomal_recessive?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency_autosomal_dominant?search=F11#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Venous Thrombosis</Disease_Name>
      <Disease_Detail>Venous Thrombosis</Disease_Detail>
      <Disease_DB>VNS009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/venous_thrombosis?search=F11#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Factor XI catalytic domain complexed with N-((R)-1-(4-bromophenyl)ethyl)urea-Asn-Val-Arg-alpha-ketothiazole</PDB_Title>
      <PDB_ID>1ZPZ</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZPZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Synthesis and Biological Evaluation of Peptidomimetic FXIa Inhibitors</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 4-Methyl-pentanoic acid {1-[4-guanidino-1-(thiazole-2-carbonyl)-butylcarbamoyl]-2-methyl-propyl}-amide</PDB_Title>
      <PDB_ID>1ZPB</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZPB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine</PubMed_Title>
      <Author>Deng, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:3049-3054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16524727?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Factor XI in complex with 4-(guanidinomethyl)-phenylboronic acid</PDB_Title>
      <PDB_ID>1ZMJ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZMJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.</PubMed_Title>
      <Author>Lazarova, T.I., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:5022-5027</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16876411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with a peptidomimetic Inhibitor</PDB_Title>
      <PDB_ID>1ZOM</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZOM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.</PubMed_Title>
      <Author>Lin, J., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:7781-7791</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17181160?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Amino-6-oxo-2-m-tolyl-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide</PDB_Title>
      <PDB_ID>1ZTK</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZTK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pyrimidinone Inhibitors of a Thrombolytic Protease</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Factor XI complexed with a pyrimidinone inhibitor</PDB_Title>
      <PDB_ID>1ZSL</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZSL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pyrimidinone Inhibitors of a Thrombolytic Protease</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the FXIa Catalytic Domain in Complex with EcotinM84R</PDB_Title>
      <PDB_ID>1XX9</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XX9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of the FXIa Catalytic Domain in Complex with Ecotin Mutants Reveal Substrate-like Interactions</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:4704-4712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15545266?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenyl)guanidine</PDB_Title>
      <PDB_ID>1ZMN</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZMN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.</PubMed_Title>
      <Author>Lazarova, T.I., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:5022-5027</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16876411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-(5-Benzylamino-2-methylsulfanyl-6-oxo-6H-pyrimidin-1-yl)-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-acetamide</PDB_Title>
      <PDB_ID>1ZTJ</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZTJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pyrimidinone Inhibitors of a Thrombolytic Protease</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with N-[4-Guanidino-1-(thiazole-2-carbonyl)-butyl]-2-{6-oxo-5-[(quinolin-8-ylmethyl)-amino]-2-m-tolyl-6H-pyrimidin-1-yl}-acetamide</PDB_Title>
      <PDB_ID>1ZTL</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZTL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pyrimidinone Inhibitors of a Thrombolytic Protease</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE OF THE A4 DOMAIN OF BLOOD COAGULATION FACTOR XI</PDB_Title>
      <PDB_ID>2J8J</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2J8J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the A4 Domain of Factor Xi Sheds Light on the Mechanism of Zymogen Activation.</PubMed_Title>
      <Author>Samuel, D., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2007)104:15693</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17884987?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure at 2.9 Angstroms resolution of human plasma coagulation factor XI zymogen</PDB_Title>
      <PDB_ID>2F83</PDB_ID>
      <Resolution>2.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F83</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the factor XI zymogen reveals a pathway for transactivation.</PubMed_Title>
      <Author>Papagrigoriou, E., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2006)13:557-558</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16699514?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 6-Carbamimidoyl-4-(3-hydroxy-2-methyl-benzoylamino)-naphthalene-2-carboxylic acid methyl ester</PDB_Title>
      <PDB_ID>1ZSK</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZSK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and Optimization of Potent and Selective Inhibitors for Human Factor XIa: Substituted Naphthamidine Series</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in complex with N-(7-Carbamimidoyl-naphthalen-1-yl)-3-hydroxy-2-methyl-benzamide</PDB_Title>
      <PDB_ID>1ZSJ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZSJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and Optimization of Potent and Selective Inhibitors for Human Factor XIa: Substituted Naphthamidine Series</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>FXI APPLE 4 DOMAIN LOOP-OUT CONFORMATION</PDB_Title>
      <PDB_ID>2J8L</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2J8L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the A4 Domain of Factor Xi Sheds Light on the Mechanism of Zymogen Activation.</PubMed_Title>
      <Author>Samuel, D., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2007)104:15693</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17884987?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Factor XIa in complex with Clavatadine A</PDB_Title>
      <PDB_ID>3BG8</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BG8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Clavatadine A, a natural product with selective recognition and irreversible inhibition of factor XIa.</PubMed_Title>
      <Author>Buchanan, M.S., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:3583-3587</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18510371?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the FXIa Catalytic Domain in Complex with mutated Ecotin</PDB_Title>
      <PDB_ID>1XXD</PDB_ID>
      <Resolution>2.91</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XXD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of the FXIa Catalytic Domain in Complex with Ecotin Mutants Reveal Substrate-like Interactions</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:4704-4712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15545266?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Human Coagulation Factor XIa in Complex with alpha-Ketothiazole Arginine Derived Ligand</PDB_Title>
      <PDB_ID>2FDA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FDA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine</PubMed_Title>
      <Author>Deng, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:3049-3054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16524727?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of the Coagulation Factor XIa in Complex with Benzamidine (S434A-T475A-K437 Mutant)</PDB_Title>
      <PDB_ID>1ZHM</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZHM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:1418-1425</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16204896?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Factor XI in complex with (R)-1-(4-(4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl)phenethyl)guanidine</PDB_Title>
      <PDB_ID>1ZML</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZML</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.</PubMed_Title>
      <Author>Lazarova, T.I., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:5022-5027</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16876411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the FXIa Catalytic Domain in Complex with Ecotin Mutant (EcotinP)</PDB_Title>
      <PDB_ID>1XXF</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XXF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structures of the FXIa Catalytic Domain in Complex with Ecotin Mutants Reveal Substrate-like Interactions</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:4704-4712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15545266?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-K505 Mutant)</PDB_Title>
      <PDB_ID>1ZHP</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZHP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:1418-1425</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16204896?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with 2-[2-(3-Chloro-phenyl)-2-hydroxy-acetylamino]-N-[4-guanidino-1-(thiazole-2-carbonyl)-butyl]-3-methyl-butyramide</PDB_Title>
      <PDB_ID>1ZPC</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZPC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, SAR exploration, and X-ray crystal structures of factor XIa inhibitors containing an alpha-ketothiazole arginine</PubMed_Title>
      <Author>Deng, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:3049-3054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16524727?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Factor XI complexed with 3-hydroxypropyl 3-(7-amidinonaphthalene-1-carboxamido)benzenesulfonate</PDB_Title>
      <PDB_ID>1ZRK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZRK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and Optimization of Potent and Selective Inhibitors for Human Factor XIa: Substituted Naphthamidine Series</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Factor XI catalytic domain complexed with 2-guanidino-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl nicotinate</PDB_Title>
      <PDB_ID>1ZLR</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZLR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.</PubMed_Title>
      <Author>Lazarova, T.I., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:5022-5027</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16876411?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Benzamidine (S434A-T475A-C482S-K437A Mutant)</PDB_Title>
      <PDB_ID>1ZHR</PDB_ID>
      <Resolution>1.73</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZHR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.</PubMed_Title>
      <Author>Jin, L., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:1418-1425</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16204896?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Catalytic Domain of Coagulation Factor XI in Complex with Kunitz Protease Inhibitor Domain of Protease Nexin II</PDB_Title>
      <PDB_ID>1ZJD</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZJD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Mutational Analyses of the Molecular Interactions between the Catalytic Domain of Factor XIa and the Kunitz Protease Inhibitor Domain of Protease Nexin 2</PubMed_Title>
      <Author>Navaneetham, D., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:36165-36175</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16085935?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.gi.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1xx9</CATH_URL>
  </Fold>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.27</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/27.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04500001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04500002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04500003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04500004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04500006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>